Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study
CONCLUSIONS: This study suggests that sirolimus monotherapy may be useful as adjuvant therapy of high-risk cSCC in kidney transplant recipients. The conversion strategy used was well tolerated and safe regarding key mid-term transplant outcomes.PMID:37565728 | DOI:10.1590/2175-8239-JBN-2023-0013en
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Authors: Marina Rezende de F ázio Marina Pontello Cristelli Jane Tomimori Carlos Eiji Koga Mar ília Marufuji Ogawa Giovanni Tani Beneventi Helio Tedesco-Silva Jos é Medina-Pestana Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Transplant | Kidney Transplantation | Skin | Squamous Cell Carcinoma | Study | Transplant Surgery | Transplants | Urology & Nephrology